Loading clinical trials...
Loading clinical trials...
Multi-center, Blinded, Randomized, Parallel-group, Phase 3 Study With Aprocitentan in Subjects With Resistant Hypertension (RHT)
Conditions
Interventions
Aprocitentan 12.5 mg
Aprocitentan 25 mg
+1 more
Locations
159
United States
Advanced Cardiovascular, LLC
Alexander City, Alabama, United States
Chrishard Medical Group
Inglewood, California, United States
Clinical Trials Research
Lincoln, California, United States
Academic Medical Research Institute Inc
Los Angeles, California, United States
Amicis Research Center
Northridge, California, United States
California Kidney Specialists
San Dimas, California, United States
Start Date
June 18, 2018
Primary Completion Date
May 14, 2021
Completion Date
April 25, 2022
Last Updated
March 21, 2023
NCT04388124
NCT07081243
NCT06940011
NCT06515795
NCT06228677
NCT06829537
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions